

Explore the latest Alzheimer's disease Biomarker Advancements Using the ALZpath pTau217 Antibody

Clinical Trials in Alzheimer's Disease (CTAD) Conference

December 1-4th, 2025 | San Diego, USA

Key Collaborator Presentations Monday, 1 December 2025

6:15pm The TRAVELLER master pre-screener protocol: An approach to reduce participant burden and broaden access to clinical trials in Alzheimer's disease

Authors: Lane et al
Institution: Roche

Tuesday, 2 December 2025

3:50pm Remote digital biomarkers for trial efficiency

Authors: Brian Murphy
Institution: Cumulus Neuroscience

Wednesday, 3 December 2025

9:15am-9:30am Longitudinal Associations Between Plasma pTau217 And Amyloid Pet

Authors: Shekari et al
Institution: University of California, Berkeley

10:40am Longitudinal Trajectories Of Plasma pTau217 In Cognitively Unimpaired Older Adults Using A Fully Automated Platform

Authors: Denking et al
Institution: Banner Sun Health Research Institute

12:05pm-12:20pm Large-Scale Plasma Proteomic Profiling Unveils Diagnostic Biomarkers And Pathways For Alzheimer's Disease

Authors: Cruchaga et al
Institution: Neurogenomics and Informatics Center, Washington University

Thursday, 4 December 2025

8:45am-9:00am pTau217 Performance To Separate Alzheimer's Disease Biological Stage Is Not Increased By Adding Demographic Or Clinical Information.

Authors: Doeke et al
Institution: CSIRO

3:55pm-4:30pm Blood based biomarker solutions for AD diagnosis

Authors: Bhatt et al
Institution: Beckman Coulter

Poster Presentations

Poster #P009 Alzheimer's Disease Pivotal Trial Design For Zervimesine Following An End Of Phase 2 Meeting With FDA

Authors: Iaci et al
Institution: Cognition Therapeutics
Monday, 1 December | 3pm

Poster #P195 Association Of Plasma Alzheimer's Disease and Neurodegeneration Biomarkers with Perceived Stress, Neighborhood Disadvantage, and Socioeconomic Status

Authors: Shekari et al
Institution: University of California, San Francisco
Wednesday, 3 December | 7:15am-5:00pm

Poster #P196 Diagnostic Accuracy Of Novel Plasma pTau217 And P-Tau181 Assays For Alzheimer's Disease

Authors: Colon-Franco et al
Institution: Cleveland Clinic
Wednesday, 3 December | 7:15am-5:00pm



Poster Presentations

Poster
#P212 Targeted Plasma Proteomic
Biomarker Profiling In The Finger
Multimodal Lifestyle Intervention Trial

Authors: Matton et al
Institution: Karolinska Institutet
Wednesday, 3 December | 7:15am–5:00pm

Poster
#P214 Age-Related Changes In Plasma
pTau217 And Reference Levels In
Cognitively Unimpaired AB –
Negative Individuals

Authors: Mammel et al
Institution: Neurocode
Wednesday, 3 December | 7:15am–5:00pm

Poster
#P215 A Comparative Analysis Of Creatinine
and Cystatin C-Based Egfr
Equations For The Assessment Of
Chronic Kidney Disease Influence On
Plasma P-Tau217 Concentrations

Authors: Bornhorst et al
Institution: Mayo Clinic
Wednesday, 3 December | 7:15am–5:00pm

Poster
#P223 Multiple Plasma Biomarker Diagnostic
Cascade: Performance Of The
Beckman Coulter pTau217, AB42, And
NFL Assays In A Cohort Of Individuals
With Cognitive Impairment

Authors: Becker et al
Institution: Beckman Coulter
Wednesday, 3 December | 7:15am–5:00pm

Poster
#P229 Differential Age Effects On Plasma
pTau217 By Amyloid Status, Cognitive
Stage, And Sex In Alzheimer's Disease

Authors: Yim et al
Institution: Samsung Medical Center
Wednesday, 3 December | 7:15am–5:00pm

Poster
#P284

The Global Neurodegeneration
Proteomics Consortium (Gnpc) V2:
Expanding Real-World Proteomics To
Include Lifestyle And Drug
Interventions, Additional
Geographies, And Multiple Proteomic

Authors: Imam et al
Institution: Gates Venture
Wednesday, 3 December | 7:15am–5:00pm

Poster
#P394

Validating A Multi-Domain Digital
Endpoint Platform (Neulogiq) For
Decentralized Alzheimer's Trials:
Results From The Cns-101 Study

Authors: Murphy et al
Institution: Cumulus Neuroscience
Wednesday, 3 December | 7:15am–5:00pm
